tailieunhanh - Beta-hydroxy beta-methylbutyrate/arginine/ glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: An open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Đang chuẩn bị liên kết để tải về tài liệu:
Beta-hydroxy beta-methylbutyrate/arginine/ glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: An open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Minh Trung 29 11 pdf

Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of β-hydroxy-β-methylbutyrate, arginine, and glutamine (HMB/Arg/Gln) was assessed in newly diagnosed patients. |

Đang chuẩn bị liên kết để tải về tài liệu: Beta-hydroxy beta-methylbutyrate/arginine/ glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: An open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of β-hydroxy-β-methylbutyrate, arginine, and glutamine (HMB/Arg/Gln) was assessed in newly diagnosed patients. |

Đang chuẩn bị liên kết để tải về tài liệu:
Beta-hydroxy beta-methylbutyrate/arginine/ glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: An open-label, multicentre, randomised, controlled phase II trial (NOURISH)